Solid tumors known to overexpress GRPR and with [68Ga]-NeoB lesion uptake. research hub

A Phase I/IIa open-label, multi-center study to evaluate the safety, tolerability, whole-body distribution, radiation dosimetry and anti-tumor activity of [177Lu]-NeoB administered in patients with advanced solid tumors known to overexpress gastrin-releasing peptide receptor (GRPR).

This study is testing a new drug for advanced solid tumours. It aims to check how safe it is, how it moves through the body, and if it can shrink certain tumours. Researchers are carefully looking at side effects and how well patients respond.